

Santen's Noto Plant Obtains Certification of ISO 14001 - All Three of Santen's Plants in Japan Are Now ISO 14001 Certified -

Osaka, Japan, January 30, 2003 --- Santen Pharmaceutical Co., Ltd. announced that its Noto Plant (Hakui-gun, Ishikawa Prefecture) had obtained certification of ISO 14001, an international standard for environmental management systems (EMS).

The Noto Plant is Santen's main plant and manufactures prescription and over-the-counter (OTC) ophthalmic pharmaceuticals. The EMS encompass all facilities within the site of the Noto Plant, from manufacturing and warehousing to the administration offices. Under the EMS, the Plant will carry out programs to reduce electricity consumption, water use and waste disposal, and to recycle wastes.

Santen has now acquired ISO 14001 certification at all three of its manufacturing plants in Japan.

Santen conducts environmental activities both actively and continuously, in line with its Environmental Policy to *"hand down the Earth to the next generation in its best form, in response to international environmental initiatives."*

[Outline of the Noto Plant's ISO 14001 EMS]

| | |
|--------------------------|---|
| Certified Date: | January 24, 2003 |
| Subject Facility: | Noto Plant, Santen Pharmaceutical Co., Ltd., including manufacturing plants, warehouses and administration offices |
| EMS Program: | To reduce the consumption of electricity, use of water and waste disposal, to increase recycling of wastes, and to promote eco-product purchases |
| Certifying Organization: | The High Pressure Gas Safety Institute of Japan |

[Outline of the Noto Plant]

Location: 2-14, Aza-shikinami, Shio-machi, Hakui-gun, Ishikawa, Japan
Lot Area: 66,665 square meters
Number of Employees: Approximately 300
Manufactured Items: Prescription ophthalmics (anti-infective *Cravit* and *Tarivid*, corneal disorder treatment *Hyalein*, etc.) and OTC eye drops (*Sante FX Neo*, *Sante 40*, etc.)

Santen specializes in the research, development, manufacture and marketing of ophthalmic and anti-rheumatic pharmaceuticals to protect and improve people's eyesight and health. Santen has created innovative pharmaceuticals for all types of ophthalmic disorders and provides information tailored to clinical needs. As a result, Santen leads Japan's market for prescription ophthalmics, which represent nearly 80 percent of Company sales.

#